Document Detail


Use of microencapsulated iron(II) fumarate sprinkles to prevent recurrence of anaemia in infants and young children at high risk.
MedLine Citation:
PMID:  12756979     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To compare the effectiveness of microencapsulated iron(II) fumarate sprinkles (with and without vitamin A), iron(II) sulfate drops, and placebo sprinkles in preventing recurrence of anaemia and to determine the long-term haematological outcomes in children at high risk of recurrence of anaemia 12 months after the end of supplementation. METHODS: A prospective, randomized, placebo-controlled design was used to study 437 Ghanaian children aged 8-20 months who were not anaemic (haemoglobin > or = 100 g/l). Four groups were given microencapsulated iron(II) fumarate sprinkles, microencapsulated iron(II) fumarate sprinkles with vitamin A, iron(II) sulfate drops or placebo sprinkles daily for six months. Primary outcome measures were change in haemoglobin and anaemic status at baseline and study end. Non-anaemic children at the end of the supplementation period were reassessed 12 months after supplementation ended. FINDINGS: Overall, 324 children completed the supplementation period. Among the four groups, no significant changes were seen in mean haemoglobin, ferritin or serum retinol values from baseline to the end of the supplementation period. During the trial, 82.4% (267/324) of children maintained their non-anaemic status. Sprinkles were well accepted without complications. At 12 months post-supplementation, 77.1% (162/210) of children with no intervention remained non-anaemic. This proportion was similar for children among the four groups. CONCLUSION: In most children previously treated for anaemia, further supplementation was not needed to maintain their non-anaemic status. These results may have important implications for community intervention programmes in which initial high-dose treatment is needed because of a high prevalence of anaemia.
Authors:
Stanley Zlotkin; Kojo Yeboah Antwi; Claudia Schauer; George Yeung
Related Documents :
23914419 - Factors associated with childhood overweight and obesity among acculturated and new imm...
17016949 - Vitamin a deficiency disorders in children and women.
16335779 - Anaemia among schoolchildren in qena governorate, upper egypt.
18654949 - Vitamin d status of socio-economically deprived children in kabul, afghanistan.
8116059 - Effect of vitamin a on diarrhoeal and respiratory complications of measles.
22094899 - Factors contributing to adherence to dietary treatment of eosinophilic gastrointestinal...
6819289 - Lithium treatment of impulsive behavior in children.
16493919 - Congenital idiopathic clubfoot: prevention of late deformity and disability by conserva...
7186319 - Assistance to the elderly as a common task of the family and social service organizations.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2003-03-25
Journal Detail:
Title:  Bulletin of the World Health Organization     Volume:  81     ISSN:  0042-9686     ISO Abbreviation:  Bull. World Health Organ.     Publication Date:  2003  
Date Detail:
Created Date:  2003-05-19     Completed Date:  2003-06-06     Revised Date:  2009-05-29    
Medline Journal Info:
Nlm Unique ID:  7507052     Medline TA:  Bull World Health Organ     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  108-15     Citation Subset:  IM    
Affiliation:
Department of Paediatrics, Centre for International Health, University of Toronto, Division of Gastroenterology and Nutrition, Canada. stanley.zlotkin@sickkids.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Anemia, Iron-Deficiency / epidemiology,  prevention & control*
Ascorbic Acid / administration & dosage
Child, Preschool
Dietary Supplements
Ferrous Compounds / administration & dosage*
Ghana / epidemiology
Humans
Infant
Placebos
Prospective Studies
Recurrence / prevention & control
Risk Factors
Chemical
Reg. No./Substance:
0/Ferrous Compounds; 0/Placebos; 141-01-5/ferrous fumarate; 50-81-7/Ascorbic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Development of pro- and antisaccades in children with attention-deficit hyperactivity disorder (ADHD...
Next Document:  Dingeman van der Vliet, veterinary artist, 1792-1866